在没有常见的并发症的记忆诊所队列中,对阿尔茨海默病生物标志物进行分析
Makrina Daniilidou1,2, Francesca Eroli1, Vilma Alanko1,2
1Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 64 Solna, Sweden.
Brain communications
|September 8, 2023
概括
这项研究表明,包括血管素在内的特定生物标志物与阿尔茨海默病的病理学和神经退行有关,即使在没有常见并发症的患者中也是如此. 识别这些由生物标志物驱动的模式突显了阿尔茨海默病的异质性和对个性化治疗的需求.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂,异质的疾病,受高血压和糖尿病等并发症的影响.
- 这些并发症对阿尔茨海默病理和神经退行症的确切机制贡献仍然不完全理解.
- 对于剖析疾病特异性机制而言,研究没有常见并发症的个体的AD病原性至关重要.
研究的目的:
- 探索AD风险机制的分子标记物与已确定的AD标记物之间的关系.
- 分析这些关联在一个特别选择的记忆诊所队列中,因为没有常见的并发症.
- 在认知障碍患者群体中识别潜在的生物标志物驱动的内类型.
主要方法:
- 分析了90名参与者脑脊液 (CSF) 中的13个分子标记 (主观认知衰退,轻度认知障碍,AD).
- 利用协同变量和线性回归分析来比较生物标志物水平并分析关联.
- 采用两步集群分析来对患者分层和对海马组织的免疫光染色进行关键标记.
主要成果:
- ангиотензиноген, thioredoxin-1, 和 介质蛋白-15 显示出与AD病理学,突触和轴突损伤标志物的显著关联.
- 在轻度认知障碍和AD组中,突触体相关蛋白25 kDa和神经纤维光链升高.
- 一个不同的患者集群 (集群1) 呈现出氧化应激,血管病理和神经炎症的CSF标志物增加,与更大的突触和轴突损伤相关.
结论:
- 与炎症,生存和血管/代谢途径相关的生物标志物与AD病理和神经退行有关.
- ангиотензиноген染色在AD海马中升高,并与酸化-tau.localized共同定位.
- 这些发现强调了阿尔茨海默病的生物学异质性,并支持制定量身定制的预防和治疗策略.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.4K
相关概念视频
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:30Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139